Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France
- Resource Type
- Authors
- François Goldwasser; Audrey Thomas-Schoemann; Galdric Orvoen; Jean-Louis Golmard; Olivier Huillard; Benoit Blanchet; Pascaline Boudou-Rouquette; Clémentine Villeminey; Anne Chah Wakilian; Michel Vidal; Esther Azoulay-Rutman; Clément Bonnet; Jérôme Alexandre; Edith Carton; Gaëlle Noé
- Source
- Cancer Chemotherapy and Pharmacology. 79:1051-1055
- Subject
- Male
Oncology
Cancer Research
Comorbidity
Pharmacists
Toxicology
030226 pharmacology & pharmacy
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
immune system diseases
Prednisone
Prevalence
Electronic Health Records
Drug Interactions
heterocyclic compounds
Pharmacology (medical)
Enzyme Inhibitors
Neoplasm Metastasis
media_common
Aged, 80 and over
Univariate analysis
Abiraterone acetate
virus diseases
Prostatic Neoplasms, Castration-Resistant
030220 oncology & carcinogenesis
Androstenes
France
medicine.drug
Drug
medicine.medical_specialty
media_common.quotation_subject
Pain
Disease-Free Survival
03 medical and health sciences
Internal medicine
parasitic diseases
medicine
Humans
Aged
Retrospective Studies
Pharmacology
Polypharmacy
business.industry
Retrospective cohort study
biochemical phenomena, metabolism, and nutrition
medicine.disease
Cross-Sectional Studies
chemistry
business
- Language
- ISSN
- 1432-0843
0344-5704
Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent may result in drug–drug interactions (DDI). We aimed to evaluate the prevalence of DDI with abiraterone and the possible determinants for the occurrence of these DDI. We performed a single centre retrospective review from electronic medical records of mCRPC patients treated with abiraterone from 2011 to 2015. Potential DDI with abiraterone were identified using Micromedex and were categorized by a 4-point scale severity. Seventy-two out of ninety-five mCRPC pts (median age: 77 years [68–82]) had comorbidities. The median number of drugs used per patient was 7 [5–9]. 66 potential DDI with abiraterone were detected in 49 patients (52%): 39 and 61% were classified as major and moderate DDI, respectively. In the univariate analysis, pain (p